Patent SG-11201910085U-A (SG)
Title: Atropine pharmaceutical compositions
Inventor: PURI NAVNEET
IPC: A61K47/38
Filed: 2018-05-10
Abstract: WO 18/ 20905 1 Al Tronskr Met.Tarrir le . Cr. POIrrwerSoutom.81,rank Figure 1 coop= ny lra, lor 1.tridlon drrArtxne. cool Gowns, 20-25 . C. CM1clotc Artrual pri Mr, 1.10rachloric um Mydroxice5olar6, =rho: IrdErtssrreinp PARlIGULATE PEOLICnON FILTPAIION irn.rj rminlararre r• r ertle Vor 6aIritiaro Stale Bulk Formulation of Arimpeullato lne.Madan nbnt• rat Ire than 60 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 November 2018 (15.11.2018) WIPO I PCT ~ill IIIIIIIIII1101DIVIIIIIIIHo o Holoiloimollmuoinio oimIE (10) International Publication Number WO 2018/209051 Al (51) International Patent Classification: A61K 9/00 (2006.01) A61K 47/18 (2006.01) A61K 9/08 (2006.01) A61K 31/46 (2006.01) A61K 47/38 (2006.01) A61P 27/02 (2006.01) (21) International Application Number: PCT/US2018/032017 (22) International Filing Date: 10 May 2018 (10.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/505,027 11 May 2017 (11.05.2017) US (71) Applicant: NEVAKAR INC. [US/US]; 1019 Route 202/206, Bldg. K, Bridgewater, New Jersey 08807 (US). (72) Inventors: PURI, Navneet; 40 Still Hollow Road, Lebanon, New Jersey 08833 (US). AKASAPU, Prem Sa- gar; 906 Rivendell Way, Edison, New Jersey 08817 (US). MOHAMMED, Irfan A.; 1900 Frontage Road, Apt. 1113, Cherry Hill, New Jersey 08034 (US). SOPPIMATH, Ku- maresh; 97 Autumn Lane, Skillman, New Jersey 08558 (US). ILITCHEV, bowl V.; 21 Reed Road, Hillsborough, New Jersey 08844 (US). ZHANG, Tao; 52 Douglas Drive, Towaco, New Jersey 07082 (US). (74) Agent: FESSENMAIER, Martin; Umberg Zipser LLP, 1920 Main Street, Suite 750, Irvine, California 92614 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: ATROPINE PHARMACEUTICAL COMPOSITIONS (57) : The inventive subject matter is directed to composi- tions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compo- sitions presented herein are substantially preservative free and ex- hibit less than 0.35% tropic acid from degradation of atropine. Ad- vantageously, contemplated formulations are also substantially free of preservatives. [Continued on next page] WO 2018/209051 Al MIDEDIM01101DEIRDEIO10010101101MOIREM01111110110111111 Published: — with international search report (Art. 21(3)) with amended claims (Art. 19(1))